drugset / Trial / NCT00203099

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

NCT00203099

Phase 2 Completed 18 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the effect of the therapy combining GA and NAC on disease activity as reflected by MRI parameters while assessing tolerability and safety.

Timeline

Start
2004-12
Primary completion
2006-08
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glatiramer Acetate Small molecule 20 mg Subcutaneous
Comparator N-acetylcysteine Small molecule 2.5 g Oral